(17) Characteristics and Treatment Patterns in Patients with Locally Advanced and Metastatic Bladder Cancer in Denmark 2015-2020

Saturday, August 27, 2022

8:00 AM – 6:00 PM CEST

Location: Hall C

Publication Number: 691

Presenting Author(s)

Mette Norgaard, MD, PhD
– Professor, MD, PhD, Department of Clinical Epidemiology, Aarhus University, Aarhus N, Midtjylland, Denmark

Co-Author(s)

Aurélie Mailhac
– Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark, Denmark
Karin Fagerlund
– Astellas Pharma A/S – Nordic Operation,, Denmark
Torsten Strunz-McKendry
– Astellas Pharma Europe Ltd, United Kingdom
Jørgen Bjerggaard Jensen
– Department of Urology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Denmark

Background: The treatment landscape is rapidly changing in locally advanced and metastatic urothelial bladder cancer (La/mUBC) yet little is known about the size and characteristics of this patient population and the current treatment patterns.

Objectives: to describe the La/mUBC population and its treatment patterns in Denmark

Methods: In a registry-based nationwide cohort study, we included all adult bladder cancer patients (18 years or older) with a recording of a La/mUBC tumor in the pathology register and a concomitant bladder cancer diagnosis registered in the Danish National Patient Registry in the period 2015-2020. We categorized the patients as 1) de novo La/mUBC i.e. patients with La/mUBC at time of first BC diagnosis and 2) progressed La/mUBC i.e. patients with non-invasive or localized muscle invasive BC at time of diagnosis who progressed to La/mUBC. All patients were included at date of pathology confirmed La/mUBC disease (index date). Follow-up for treatment, hospital admissions, and death started at index date and ended at date of death or August 31, 2021, whichever occurred first.

Results: We identified 494 patients with pathologically confirmed La/mUBC and no other previous cancer in the period 2015-2020. Of these, 60 (12.2%) had La/mUBC at time of their first BC diagnosis (de novo) while the remaining 434 had progressed to La/mUBC. Of the 494 patients, 73.5% were men, 75.7% were 65 years or older. At time of study inclusion, 60.3% had no comorbidity registered according to Charlson comorbidity index. The patients were followed for a median of 1.4 years (interquartile range: 0.6;2.6). The median survival from index date was 17.5 months for the overall population. Among 230 patients who received first line systemic treatment, median survival from start of 1st line treatment was 12.6 months. For 92 patients who had second line treatment, median survival from start of 2nd line treatment was 10.2 months. For 40 patients who received a third line treatment, median survival was 8.3 months from start of third line treatment. The mean number of days spent in hospital per month was 2.90 following 1st line treatment 3.51 following 2nd line treatment and 3.08 following third line treatment.

Conclusions: The Danish medical databases may be a useful resource to describe treatment patterns in patients with La/mUBC.